HOTH Stock Analysis: Buy, Sell, or Hold?
HOTH - Hoth Therapeutics, Inc. Common Stock
$0.63
-0.03 (-4.94%)
▼
5d:
-5.54%
30d:
-14.83%
90d:
-37.94%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Get Alerted When HOTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called HOTH this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HOTH shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: HOTH shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: HOTH is currently trading at $0.63, which is considered slightly low relative to its 30-day fair value range of $0.62 to $0.77.
Technical Outlook: Technically, HOTH is in a strong downtrend. The price is currently testing key support at $0.63. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: HOTH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.00 (+689.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HOTH is in a strong downtrend. The price is currently testing key support at $0.63. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: HOTH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.00 (+689.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.62 -
$0.77
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 689.9% below Wall St target ($5.00)
- CAUTION: 5-day price weakness (-5.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.62 -
$0.77
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.63
Resistance Level
$0.75
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.90
Wall Street Target
$5.00
(+689.9%)
Share & Embed Analysis
Last updated: May 18, 2026 6:17 AM ET
Data refreshes hourly during market hours. Next update: 7:17 AM
Data refreshes hourly during market hours. Next update: 7:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 63 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
